Boston Scientific
BSX
$42.04
+1.11%
Boston Scientific Corp. is a global medical device manufacturer focused on less invasive technologies inserted into the human body through small openings, spanning interventional cardiology, cardiac rhythm management, electrophysiology, endoscopy, urology, neuromodulation, and peripheral interventions, with roughly 36% of sales generated outside the United States. The company is a scaled medtech leader with approximately 59,000 employees, competing against Abbott, Medtronic, and Johnson & Johnson in most of its end markets, and it is best characterized as a diversified, innovation-driven platform rather than a single-product franchise. The current investor narrative has turned sharply negative: the stock has lost more than half its value over the past year, with headlines citing underwhelming clinical trial results in late March and a broad large-cap sell-off, while management simultaneously pursues a $1.5 billion bet on MiRus's novel TAVR technology to attack the growing aortic stenosis market. The debate now centers on whether the sell-off is an overreaction to pipeline setbacks and a temporary growth air pocket, or a genuine de-rating reflecting competitive losses and slowing procedure volumes, with the MiRus deal framed by bulls as a low-risk entry into a high-growth adjacent market.…
BSX
Boston Scientific
$42.04
Related headlines
Investment Opinion: Should I buy BSX Today?
The synthesized recommendation is a Hold with a speculative bias. The core thesis is that Boston Scientific's 55% price decline has created a deep value opportunity, with a forward PE of 12.49x and analyst average target of $60.79 implying 42.7% upside, but the unresolved pipeline setbacks and negative momentum warrant caution until there is clearer evidence of a turnaround. The analyst consensus rating of Buy (1.65 mean) and the wide target range ($44-$94) reflect high uncertainty, making this a high-risk, high-reward situation.
Supporting evidence for a Hold includes: 1) Revenue growth of 7.53% year-over-year in Q2 2026, with a 70.71% gross margin and 19.78% operating margin, demonstrating underlying profitability; 2) Free cash flow of $3.625 billion, which provides financial flexibility; 3) Forward PE of 12.49x, which is well below the trailing PE of 48.65x and suggests the market is pricing a recovery; and 4) Analyst average target of $60.79, implying significant upside. However, the price-to-sales ratio of 7.03x and EV/EBITDA of 29.70x are not cheap, and the 55.73% one-year decline reflects deep-seated concerns.
The biggest risks that could invalidate the thesis are: 1) Further pipeline failures or competitive losses that delay the earnings recovery; 2) A failure of the MiRus TAVR investment to gain traction; and 3) Continued negative momentum that drives the stock below its 52-week low of $41.94. The rating would upgrade to Buy if the stock stabilizes above $50 and forward EPS estimates are revised upward, or downgrade to Sell if revenue growth decelerates below 5% or if the stock breaks below $40. Relative to its history and peers, the stock appears undervalued on forward earnings but fairly valued on sales and EBITDA, suggesting a balanced risk/reward.
Sign up to view all
BSX 12-Month Price Forecast
The forward-looking view is cautiously neutral. The stock's deep decline has created a valuation disconnect, with forward PE at 12.49x and analyst targets implying substantial upside, but the unresolved pipeline issues and negative momentum are significant overhangs. The base case (55% probability) sees the stock recovering to the $55-65 range as earnings normalize, while the bull case (25%) and bear case (20%) represent more extreme outcomes. I would upgrade to bullish if the stock stabilizes above $50 and there is clear evidence of pipeline success, and downgrade to bearish if it breaks below $40 or if revenue growth decelerates below 5%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Boston Scientific's 12-month outlook, with a consensus price target around $59.90 and implied upside of +42.5% versus the current price.
Average Target
$59.90
0 analysts
Implied Upside
+42.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$44 - $94
Analyst target range
Bulls vs Bears: BSX Investment Factors
The bear case currently has stronger evidence due to the stock's relentless decline, negative relative strength, and unresolved pipeline concerns. However, the bull case rests on a compelling valuation disconnect: forward PE of 12.49x and analyst targets implying 42.7% upside suggest the market may be overly pessimistic. The single most important tension is whether the late-March trial setback is a temporary air pocket or a sign of structural competitive losses; if upcoming data and the MiRus TAVR bet restore confidence, the stock could re-rate sharply, but if execution falters, the downtrend may continue.
Bullish
- Deep Value on Forward Earnings: Forward PE of 12.49x is less than a third of the trailing PE of 48.65x, implying the market is pricing a massive earnings recovery. Analyst consensus EPS of $4.52 for the current year would represent a more than 200x increase from the trailing EPS of $0.02, suggesting the trailing figure is distorted by one-time items and that the forward multiple is the more relevant valuation anchor.
- Analyst Consensus Strongly Bullish: All 29 covering analysts rate the stock a Buy (mean recommendation 1.65), with an average target price of $60.79, implying 42.7% upside from the current $42.60. The high target of $94.00 suggests some analysts see more than 120% upside, indicating a wide disconnect between market pricing and analyst expectations.
- Profitability and Cash Generation Intact: Q2 2026 revenue grew 7.53% year-over-year to $5.442 billion, with a 70.71% gross margin and 19.78% operating margin. The company generated $3.625 billion in trailing free cash flow, demonstrating that the core business remains highly cash-generative despite the stock's collapse.
- Low Beta Defensive Profile: Beta of 0.568 indicates the stock is significantly less volatile than the broader market, which is unusual for a stock that has fallen 55.7% in a year. This suggests the sell-off is driven by company-specific factors rather than systematic market risk, and the low beta may attract defensive investors once the overhang clears.
Bearish
- Catastrophic Price Collapse and Underperformance: The stock has plummeted 55.73% over the past year and 55.02% year-to-date, massively underperforming the S&P 500's 15.01% and 12.86% gains over the same periods. Relative strength is deeply negative across all timeframes, with a 1-year relative strength of -70.74, indicating severe and sustained weakness.
- Pipeline Setbacks and Competitive Losses: Underwhelming clinical trial results in late March triggered a sharp sell-off, and the stock has continued to make lower lows, falling from a 52-week high of $105.65 to a low of $41.94. The market appears to be pricing in lost market share and delayed product launches, which could impair future growth.
- Trailing Profitability Metrics Are Weak: Trailing EPS of $0.02 and a trailing PE of 48.65x suggest that recent earnings have been minimal, likely due to one-time charges or impairments. The net margin of 14.38% is respectable but the trailing PE is extremely high, indicating that the market is paying a premium for uncertain future earnings.
- High Valuation Relative to Sales and EBITDA: Price-to-sales of 7.03x and EV/EBITDA of 29.70x are elevated for a medtech company with mid-single-digit revenue growth. Even after the price decline, the stock is not cheap on these metrics, suggesting further downside if growth does not accelerate.
BSX Technical Analysis
Beta
0.57
0.57x market volatility
Max Drawdown
-61.5%
Largest decline past year
52-Week Range
$41-$106
Price range past year
Annual Return
-56.6%
Cumulative gain past year
| Period | BSX Return | S&P 500 |
|---|---|---|
| 1m | -6.5% | +1.0% |
| 3m | -6.1% | +2.5% |
| 6m | -32.0% | +13.9% |
| 1y | -56.6% | +15.0% |
| ytd | -55.6% | +13.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BSX Fundamental Analysis
Quarterly Revenue
$5.4B
2026-06
Revenue YoY Growth
+7.5%
YoY Comparison
Gross Margin
70.7%
Latest Quarter
Free Cash Flow
$3.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BSX Overvalued?
PE
48.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 17x~87x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant given the company's recent earnings volatility. Trailing EPS of $0.02 and a trailing PE of 48.65x indicate that profitability has been severely depressed, likely due to one-time charges or impairments, while the forward PE of 12.49x relies on a dramatic earnings recovery that may not materialize. Although debt-to-equity of 0.51 is manageable and free cash flow of $3.625 billion provides ample liquidity, the 7.53% revenue growth is modest for a company trading at 7.03x sales, and any deceleration could pressure the valuation further. Additionally, the $1.5 billion MiRus investment represents a significant capital commitment that may not pay off if the TAVR technology fails to gain regulatory approval or market acceptance.
Market and competitive risks are heightened by the stock's extreme underperformance and negative momentum. The stock has fallen 55.73% over the past year, with a relative strength of -70.74 versus the S&P 500, reflecting a severe loss of investor confidence. Beta of 0.568 suggests lower market correlation, but the sell-off is company-specific, driven by underwhelming trial results and competitive pressures from larger medtech peers like Abbott and Medtronic. The high EV/EBITDA of 29.70x leaves little room for error; if growth slows or margins compress, multiple contraction could drive further downside. Recent news highlights the MiRus deal as a strategic positive, but execution risks and integration challenges could offset its benefits.
In a worst-case scenario, continued pipeline failures, market share losses, and a failure to achieve the projected earnings recovery could push the stock below its 52-week low of $41.94. The analyst low target of $44.00 is only 3.3% above the current price, indicating that even the most bearish analyst sees limited downside from here, but a break below $41.94 could trigger a new leg down toward the $35-40 range. From the current price of $42.60, a decline to the 52-week low represents a 1.5% loss, but if the stock revisits its historical max drawdown of -60.61% from the high, it could fall to around $41.60, implying a 2.3% downside. However, in a severe scenario where the MiRus bet fails and core growth turns negative, the stock could drop 20-30% to the low $30s, though this is not supported by current analyst targets.
FAQ
The key risks for BSX are ranked as follows: 1) Pipeline and competitive risk: underwhelming clinical trial results in late March have raised concerns about the company's ability to innovate, and competitors like Abbott and Medtronic could gain market share. 2) Valuation risk: despite the price decline, the stock still trades at 7.03x sales and 29.70x EV/EBITDA, leaving room for further downside if growth disappoints. 3) Financial risk: trailing EPS of $0.02 and a high trailing PE of 48.65x indicate earnings volatility, and the $1.5 billion MiRus investment could strain resources if it fails. 4) Macro risk: with a beta of 0.568, the stock is less sensitive to market swings, but a broad economic slowdown could reduce procedure volumes and hurt revenue.
The 12-month forecast for BSX includes three scenarios: bull case (25% probability) with a target range of $75-$94, assuming successful pipeline execution and MiRus TAVR approval; base case (55% probability) with a target range of $55-$65, assuming gradual recovery and EPS meeting the $4.52 consensus; and bear case (20% probability) with a target range of $35-$44, assuming continued setbacks and a break below the 52-week low. The base case is most likely, driven by the assumption that revenue growth stabilizes around 7-8% and the company meets earnings expectations. The key catalyst for the bull case would be positive clinical data, while the bear case would be triggered by further pipeline failures.
BSX appears undervalued on forward earnings but fairly valued on sales and EBITDA. The forward PE of 12.49x is significantly lower than the trailing PE of 48.65x, suggesting the market expects a strong earnings recovery. However, the price-to-sales ratio of 7.03x and EV/EBITDA of 29.70x are not cheap for a company with 7.53% revenue growth. Compared to its own history, the stock is trading at a deep discount to its 52-week high of $105.65, but the high valuation multiples on sales and EBITDA indicate that the market is still pricing in growth. The valuation implies that the market expects the company to execute on its pipeline and return to mid-single-digit growth, but any disappointment could lead to further multiple compression.
From a risk/reward perspective, BSX presents a compelling but high-risk opportunity. The stock trades at $42.60, with analyst average target of $60.79 implying 42.7% upside, and a forward PE of 12.49x that is well below the trailing PE of 48.65x. However, the company has faced pipeline setbacks and the stock is down 55.73% over the past year, with a 52-week low of $41.94 just below the current price. The biggest downside risk is a break below that low, which could lead to further declines. For risk-tolerant investors with a long-term horizon, BSX could be a good buy if they believe in the company's diversified portfolio and the potential of the MiRus TAVR investment. It is less suitable for conservative investors or those seeking income, as the stock pays no dividend.
BSX is more suitable for long-term investment than short-term trading. The company is in a turnaround phase, with a beta of 0.568 indicating lower volatility, but the stock has experienced a max drawdown of -60.61% and is down 55.73% over the past year, making it risky for short-term traders. The lack of a dividend (payout ratio 0%) means returns depend entirely on capital appreciation, which requires patience. Earnings visibility is low due to pipeline uncertainties, but the diversified portfolio and strong free cash flow of $3.625 billion support a long-term thesis. A suggested minimum holding period is 2-3 years to allow for pipeline readouts and the MiRus investment to contribute.